FibroGen lands $40M milestone from Astellas - Bizjournals.com PDF Print
Bizjournals.com
... established clinical proof-of-concept, and screening for patients in the Phase IIb began in fourth-quarter 2010. Privately held FibroGen, based in San Francisco, said the drug is aimed at chronic kidney disease patients on dialysis or not on dialysis.
FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.